Ashton Thomas Private Wealth’s Quest Diagnostics DGX Stock Holding History

Ashton Thomas Private Wealth’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.84M	Buy	9,370 +406	+5%	+$78.9K	0.04%	385
2025 Q4	$1.56M	Buy	8,964 +473	+6%	+$86.1K	0.04%	368
2025 Q3	$1.62M	Buy	8,491 +1,647	+24%	+$292K	0.04%	363
2025 Q2	$1.23M	Buy	6,844 +2,285	+50%	+$397K	0.04%	368
2025 Q1	$771K	Buy	4,559 +383	+9%	+$62.9K	0.03%	445
2024 Q4	$630K	Buy	+4,176	New	+$650K	0.02%	482
2024 Q3	–	Sell	-111	Closed	-$15.3K	–	922
2024 Q2	$15.3K	Buy	+111	New	+$15.2K	﹤0.01%	1223
2020 Q2	–	Sell	-9,951	Closed	-$799K	–	238
2020 Q1	$799K	Buy	+9,951	New	+$1.03M	0.33%	88

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Ashton Thomas Private Wealth's DGX Position: Q1 2026 in Review

Ashton Thomas Private Wealth increased its Quest Diagnostics (DGX) stake by 4.5% in Q1 2026, buying an estimated $78.9K and bringing the position to 9,370 shares worth $1.84M. The position accounts for 0.04% of the portfolio, ranked #385.

Ashton Thomas Private Wealth first reported a position in DGX in Q1 2020 and has held it in 8 quarters since. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Ashton Thomas Private Wealth held 9,370 shares of Quest Diagnostics worth $1.84M as of Q1 2026.
Ashton Thomas Private Wealth bought 406 Quest Diagnostics shares in Q1 2026, an estimated $78.9K.
Quest Diagnostics made up 0.04% of Ashton Thomas Private Wealth's portfolio in Q1 2026, its #385 holding.
Ashton Thomas Private Wealth first reported a position in Quest Diagnostics in Q1 2020 and has held it in 8 quarters since.
1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Ashton Thomas Private Wealth's 13F filing for Q1 2026, filed 11 May 2026.